A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Davis
- Dates
- study startedestimated completion
- Principal Investigator
- by Karen P Kelly (ucdavis)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UC Cancer
- Karen P Kelly (ucdavis)
Professor, Hematology and Oncology. Authored (or co-authored) 166 research publications.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- ID
- NCT04148937
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated